dimethyl aminomethylphosphonate | 50918-71-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: dimethyl aminomethylphosphonate
• 英文别名: Dimethyl (aminomethyl)phosphonate；dimethoxyphosphorylmethanamine
• CAS: 50918-71-3
• 化学式: C₃H₁₀NO₃P
• mdl: MFCD19203560
• 分子量: 139.091
• InChiKey: BXLLINKJZLDGOX-UHFFFAOYSA-N

物化性质

• 沸点：
  194.4±23.0 °C(Predicted)
• 密度：
  1.172±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  dimethyl aminomethylphosphonate 在 溶剂黄146 、 sodium nitrite 作用下， 以 甲醇 为溶剂， 生成 dimethyl diazomethylphosphonate
  参考文献：
  名称：

  通过重氮甲基膦酸酯的 1,4-脱芳烃加成，银催化活性 N-杂芳烃的扩环

  摘要：

  含磷氮杂环由于其独特的结构特征和生物活性而成为重要的分子基序。在这项研究中，我们开发了一种银催化反应，通过多米诺型脱芳构化程序构建含磷氮杂庚因衍生物，然后进行扩环。此外，重氮甲基膦酸酯首次在活化的 N-杂芳烃的 1,4-脱芳烃加成反应中用作亲核试剂，提供环丙烷稠合的哌啶中间体，这些中间体很容易重组为相应的吖庚因衍生物。发现重氮甲基膦酸酯在开发的脱芳构化策略中的反应性优于其他重氮化合物，

  DOI：

  10.1055/a-2004-1279
• 作为产物：
  描述：

  dimethyl N-(benzyloxycarbonyl)aminomethylphosphonate 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以100%的产率得到dimethyl aminomethylphosphonate
  参考文献：
  名称：

  Targeting ACE and ECE with dual acting inhibitors

  摘要：

  A series of urea analogues related to SA6817 and a GSK phosphonic acid with reported ACE inhibitory activity were prepared and tested for dual ACE and ECE activities. Although excellent ACE and NEP inhibition was achieved, only modest ECE inhibition was observed with one analogue. (C) 2008 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2007.12.013

文献信息

• Structure-activity studies of the inhibition of serine β-lactamases by phosphonate monoesters
  作者：Naixin Li、Jubrail Rahil、Margaret E. Wright、R.F. Pratt

  DOI：10.1016/s0968-0896(97)00103-x

  日期：1997.9

  of a good leaving group, 2,4-dinitrophenoxide, with an amido side-chain, phenylmethylsulfonamido--the latter rather than phenylacetamido in order to increase the stability of the compound with respect to intramolecular nucleophilic catalysis of hydrolysis by the amide group--did not yield overall a better inhibitor than previously employed p-nitrophenyl phosphonates. These results give the first indication

  制备了一系列新的膦酰基衍生物，并测试了其对丝氨酸（A和C类）β-内酰胺酶的抑制作用。一系列甲基膦酸酯中离去基团的变化表明，离去基团比以前使用的对硝基苯氧基更好，可以提供更有效的抑制剂。在离去基团中包含负电荷本身并不导致更好的抑制剂。芳基膦酸酯似乎比具有电子可比性但离去基团较小的膦酸酯更有效。一个良好的离去基团2,4-二硝基苯氧基与一个酰胺侧链的结合，相对于酰胺基团的分子内亲核催化水解作用，苯基甲基磺酰胺基（而不是苯基乙酰酰胺基）是为了提高化合物在分子内亲核催化方面的稳定性，但与以前使用的对硝基苯基膦酸酯相比，总的来说并不能产生更好的抑制剂。这些结果首次表明了β-内酰胺酶与膦酸酯抑制剂的离去基团之间的特异性相互作用。手性硫代膦酸酯的仅一种对映异构体，可能是Rp异构体，是有效的抑制剂。在对硝基苯基酰胺基甲基膦酸酯的亚甲基上添加D-或L-甲基并没有增强膦酸酯的抑制能力。A类β-内酰胺酶对膦酸酯仍
• [EN] BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS<br/>[FR] ANALOGUES DE L'ARYLOMYCINE À SPECTRE ANTIBIOTIQUE LARGE
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2013138187A1

  公开（公告）日：2013-09-19

  Arylomycin analogs are provided, wherein the analogs can have broad spectrum bioactivity. Resistance to the antibiotic bioactivity of natural product arylomycin in a range of pathogenic bacterial species has been found to depend upon single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases), wherein the presence of a proline residue confers arylomycin resistance. Arylomycin analogs are provided herein that can overcome that resistance and provide for a broader spectrum of antibiotic bioactivity than can natural product arylomycins such as arylomycin A2. Methods for determining if a bacterial strain is susceptible to narrow spectrum arylomycin antibiotics, or if a broad spectum analog is required for treatment, is provided. Pharmaceutical compositions and methods of treatment of bacterial infections, and methods of synthesis of arylomycin analogs, are provided.

  提供了芳基霉素类似物，其中这些类似物可以具有广谱生物活性。已发现在一系列致病性细菌物种中，对天然产物芳基霉素的抗生素活性的抗性取决于细菌信号肽酶（SPases）的特定位置的单个氨基酸突变，其中脯氨酸残基的存在赋予了芳基霉素抗性。本文提供了可以克服该抗性并提供比芳基霉素A2等天然产物芳基霉素更广谱抗生素活性的芳基霉素类似物。提供了用于确定细菌菌株是否对窄谱芳基霉素抗生素敏感，或者是否需要广谱类似物进行治疗的方法。提供了用于治疗细菌感染的药物组合物和方法，以及芳基霉素类似物的合成方法。
• Phosphono/biaryl substituted dipetide derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US05294632A1

  公开（公告）日：1994-03-15

  The invention relates to the N-phosphonomethyl-biaryl substituted dipeptide derivatives of formula I ##STR1## and tetrazole derivatives of the formula Ia ##STR2## wherein A represents a direct bond, lower alkylene, phenylene or cyclohexylene; m represents 1 or zero, provided that m represents 1 when A is a direct bond; R.sub.2 represents hydrogen, hydroxy, lower alkyl, aryl-lower alkyl, C.sub.5 -C.sub.7 -cycloalkyl-lower alkyl, amino-lower alkyl, hydroxy-lower alkyl, lower alkylthio-lower alkyl, lower alkoxy-lower alkyl, aryl-lower alkylthio-lower alkyl or aryl-lower alkoxy-lower alkyl; biaryl represents phenyl substituted by carbocyclic or heterocyclic aryl; and pharmaceutically acceptable mono-, di- or tri-ester derivatives thereof in which one, two or three of the acidic hydroxy groups of the carboxyl and/or phosphono functional groups are esterified in form of a mono-, di- or tri-pharmaceutically acceptable ester; and pharmaceutically acceptable amide derivatives thereof wherein the carboxyl group is derivatized in form of a pharmaceutically acceptable amide; and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; methods for the preparation of said compounds and for the preparation of intermediates; and methods of treating disorders in mammals which are responsive to the inhibition of neutral endopeptidases by administration of said compounds to mammals in need of such treatment.

  该发明涉及公式I的N-磷酸甲基-联苯基取代二肽衍生物以及公式Ia的四唑衍生物，其中A代表直接键，较低的烷基，苯基或环己烷基；m代表1或零，但当A为直接键时，m代表1；R.sub.2代表氢，羟基，较低的烷基，芳基-较低的烷基，C.sub.5-C.sub.7-环烷基-较低的烷基，氨基-较低的烷基，羟基-较低的烷基，较低的硫代烷基-较低的烷基，较低的氧代烷基-较低的烷基，芳基-较低的烷基硫代烷基或芳基-较低的烷基氧代烷基；联苯基代表被碳环或杂环芳基取代的苯基；以及其药学上可接受的单酯、二酯或三酯衍生物，其中羧基和/或磷酸基的酸性羟基中的一个、两个或三个以单酯、二酯或三酯药学上可接受的酯的形式酯化；以及其药学上可接受的酰胺衍生物，其中羧基以药学上可接受的酰胺形式衍生化；以及其药学上可接受的盐；包括所述化合物的药物组合物；制备所述化合物和中间体的方法；以及通过向需要此类治疗的哺乳动物施用所述化合物来抑制中性内肽酶以治疗哺乳动物疾病的方法。
• Phosphono/biaryl substituted dipeptide derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US05155100A1

  公开（公告）日：1992-10-13

  The invention relates to the N-phosphonomethyl-biaryl substituted dipeptide derivatives of formula I ##STR1## wherein A represents a direct bond, lower alkylene, phenylene or cyclohexylene; m represents 1 or zero, provided that m represents 1 when A is a direct bond; R.sub.2 represents hydrogen, hydroxy, lower alkyl, aryl-lower alkyl, C.sub.5 -C.sub.7 -cycloalkyl-lower alkyl, amino-lower alkyl, hydroxyl-lower alkyl, lower alkylthio-lower alkyl, lower alkoxy-lower alkyl, aryl-lower alkylthio-lower alkyl or aryl-lower alkoxy-lower alkyl; biaryl represents phenyl substituted by carbocyclic or heterocyclic aryl; and pharmaceutically acceptable mono-, di- or tri-ester derivatives thereof in which one, two or three of the acidic hydroxy groups of the carboxyl and phosphono functional groups are esterified in form of a mono-, di- or tri- pharmaceutically acceptable ester; and pharmaceutically acceptable amide derivatives thereof wherein the carboxyl group is derivatized in form of a pharmaceutically acceptable amide; and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; methods for the preparation of said compounds and for the preparation of intermediates; and methods of treating disorders in mammals which are responsive to the inhibition of neutral endopeptidases by administration of said compounds to mammals in need of such treatment.

  该发明涉及公式I的N-磷酸甲基-联苯基取代二肽衍生物，其中A代表直链键，较低的烷基，苯基或环己烷基；m代表1或零，前提是当A为直链键时m代表1；R.sub.2代表氢，羟基，较低的烷基，芳基-较低的烷基，C.sub.5-C.sub.7-环烷基-较低的烷基，氨基-较低的烷基，羟基-较低的烷基，较低的硫代烷基-较低的烷基，较低的氧代烷基-较低的烷基，芳基-较低的烷基硫代烷基或芳基-较低的烷基氧代烷基；联苯基代表被碳环或杂环芳基取代的苯基；以及其药学上可接受的单酯，二酯或三酯衍生物，其中羧基和磷酸甲酯官能团的三个酸性羟基中的一个，两个或三个以单酯，二酯或三酯药学上可接受的酯的形式酯化；以及其药学上可接受的酰胺衍生物，其中羧基以药学上可接受的酰胺形式衍生化；以及其药学上可接受的盐；包括所述化合物的药物组合物；制备所述化合物和中间体的方法；以及通过向需要此类治疗的哺乳动物施用所述化合物来抑制中性内肽酶以治疗哺乳动物疾病的方法。
• Phosphonate Diester and Phosphonamide Synthesis. Reaction Coordinate Analysis by ³¹P NMR Spectroscopy:  Identification of Pyrophosphonate Anhydrides and Highly Reactive Phosphonylammonium Salts¹
  作者：Ralph Hirschmann、Kraig M. Yager、Carol M. Taylor、Jason Witherington、Paul A. Sprengeler、Barton W. Phillips、William Moore、Amos B. Smith

  DOI：10.1021/ja962465o

  日期：1997.9.1

  A series of phosphonochloridates was prepared from the corresponding phosphonate monoesters, and their reactions with alcohols, amines, and the bisnucleophile 4-aminobutan-1-ol have been investigated using 31P NMR spectroscopy. In the conversion of phosphonate monoesters to phosphonochloridates via the addition of thionyl chloride or oxalyl chloride, pyrophosphonate anhydrides were found to be formed

  从相应的膦酸酯单酯制备了一系列膦酰氯，并使用 31 P NMR 光谱研究了它们与醇、胺和双亲核试剂 4-氨基丁-1-醇的反应。在通过加入亚硫酰氯或草酰氯将膦酸单酯转化为膦酰氯时，发现焦膦酸酐很容易作为副产物形成。酸酐很容易与醇反应，但比相应的膦酰氯反应更慢，而且与胺反应也很缓慢，如果有的话。因此，在制备膦酰胺时，必须抑制酸酐的形成。这是在将单酯添加到氯化剂中时完成的。不受阻碍的膦酰氯主要与 4-氨基丁-1-醇的氨基官能团反应以提供膦酰胺，而空间位阻的膦酰氯表现出对 O 偶联的偏好。该结果表明在 P−O b 期间获得的能量...